Jill CPA - Vaccinex Chief Officer
Executive
Jill CPA is Chief Officer of Vaccinex
| Age | 52 |
| Phone | 585 271 2700 |
| Web | https://www.vaccinex.com |
Vaccinex Management Efficiency
The company has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities.Vaccinex currently holds 247 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Vaccinex has a current ratio of 8.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vaccinex's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chandra MS | Erasca Inc | 54 | |
| Robert Shoemaker | Erasca Inc | 44 | |
| Paul Little | Eledon Pharmaceuticals | 60 | |
| JD Esq | Erasca Inc | 53 | |
| John Herberger | Eledon Pharmaceuticals | N/A | |
| Mary Grendell | Protara Therapeutics | N/A | |
| John Niles | GeoVax Labs | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 55 | |
| Patrick MBA | Protara Therapeutics | 57 | |
| Li Yang | Surrozen | 56 | |
| MPH MD | Salarius Pharmaceuticals | N/A | |
| FACS FACS | Eledon Pharmaceuticals | N/A | |
| Bryan JD | Eledon Pharmaceuticals | 46 | |
| MD MBA | SAB Biotherapeutics | 53 | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Thomas OBrien | GeoVax Labs | N/A | |
| Carlos Carillo | SAB Biotherapeutics | N/A | |
| Esther Jhun | Surrozen | N/A | |
| MS CPA | Erasca Inc | 58 | |
| Leesa Gentry | RenovoRx | 55 | |
| Justine OMalley | Protara Therapeutics | N/A | |
Management Performance
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 |
Vaccinex Leadership Team
Elected by the shareholders, the Vaccinex's board of directors comprises two types of representatives: Vaccinex inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaccinex. The board's role is to monitor Vaccinex's management team and ensure that shareholders' interests are well served. Vaccinex's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaccinex's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jill CPA, Chief Officer | ||
| Jill Sanchez, Interim Controller | ||
| MBA CFA, Chief Officer | ||
| Ernest Smith, Senior Officer | ||
| Maurice Zauderer, CEO, CoFounder | ||
| Elizabeth Evans, COO Medicine | ||
| John Leonard, Senior Development |
Vaccinex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaccinex a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 | ||||
| Current Valuation | 1.59 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 11.50 % | ||||
| Shares Owned By Institutions | 51.30 % | ||||
| Number Of Shares Shorted | 62.11 K | ||||
| Price To Book | 7.34 X | ||||
| Price To Sales | 4.34 X | ||||
| Revenue | 570 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Vaccinex Stock
If you are still planning to invest in Vaccinex check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccinex's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |